BRISBANE, Calif.--(BUSINESS WIRE)--Aug. 5, 2015--
Aimmune Therapeutics, Inc. today announced the pricing of its initial
public offering of 10,000,000 shares of its common stock at a public
offering price of $16.00 per share, before underwriting discounts and
commissions. In addition, Aimmune has granted the underwriters a 30-day
option to purchase up to an additional 1,499,999 shares of common stock
at the same price. Aimmune’s common stock is expected to begin trading
on The NASDAQ Global Select Market on August 6, 2015 under the symbol
The offering is expected to close on August 11, 2015, subject to
satisfaction of customary closing conditions.
BofA Merrill Lynch, Credit Suisse and Piper Jaffray are acting as joint
book-running managers for the offering.
A registration statement relating to the securities being sold in this
offering was declared effective by the Securities and Exchange
Commission on August 5, 2015. The offering of these securities is being
made only by means of a prospectus, copies of which may be obtained
from: BofA Merrill Lynch, Attention: Prospectus Department, 222
Broadway, New York, NY 10038, or by emailing firstname.lastname@example.org;
Credit Suisse Securities (USA) LLC, Attention: Prospectus Department,
One Madison Avenue, New York, NY 10010, or by calling (800) 221-1037, or
by emailing email@example.com;
or Piper Jaffray & Co., Attention: Prospectus Department, 800 Nicollet
Mall, J12S03, Minneapolis, MN 55402, or by calling (800) 503-4611, or by
This press release shall not constitute an offer to sell or the
solicitation of an offer to buy, nor shall there be any sale of, these
securities in any state or jurisdiction in which such offer,
solicitation, or sale would be unlawful prior to registration or
qualification of these securities under the securities laws of any such
state or jurisdiction.
About Aimmune Therapeutics
Aimmune Therapeutics, Inc., founded in 2011 as Allergen Research
Corporation (ARC), is a clinical-stage biopharmaceutical company
developing treatments for peanut allergy and other food allergies.
Aimmune Therapeutics’ characterized oral desensitization immunotherapy
(CODIT™) system, an approach to oral immunotherapy (OIT), uses
rigorously characterized product candidates with gradual, controlled
up-dosing protocols to obtain clinically meaningful desensitization to
food allergens. Aimmune Therapeutics recently completed a Phase 2 study
of its lead product, AR101, a complex mixture of naturally occurring
proteins and pharmaceutical-grade ingredients for the treatment of
peanut allergy, one of the most common food allergies.
View source version on businesswire.com: http://www.businesswire.com/news/home/20150805006854/en/
Source: Aimmune Therapeutics, Inc.
Marissa Nakamichi, 323-202-1029